75N91020F00010↗

Name: 75N91020F00010: Initiate the Management, Oversight, and Conduct of the Niaid Dmid Clinical Trial Titled "a Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Covid-19".
Creator: SpendQuery

INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19".

Delivery Order · National Institutes of Health · to Leidos Biomedical Research Inc (UEI HV8BH9BPG8Y9) · data as of 2026-09-30

Obligated to date-$11.00M2 actions

Current value$72.44Mwith options exercised

Period2020-04-01 → 2023-12-31current end date

What it is

Product or service: Health R&D Services; Health Care Services; Applied Research (PSC AN12)
Industry: Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
Contracting office: Nih Nci (75N910)
Competition: Full and open competition
Pricing: Cost plus fixed fee
How it was bought: Single-award IDIQ · under 75N91019D00024
Where the work is: Frederick, MD · district MD-06
Funding law: COVID-19 laws
Topics: covid

Obligations by fiscal year

FY2023-$11.00M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

2 actions since 2023-05-01. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2023-09-28	P00008	Administrative change	$0	INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19".
2023-05-01	P00007	Administrative change	-$11.00M	INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19".

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗